Treatment disparities drive worse outcomes for pediatric Black, Hispanic brain cancer pts

March 12, 2020

Cancer researchers have known for years that Black and Hispanic patients have worse outcomes than their non-Hispanic White peers. At least when it comes to adults. But few studies have explored these same disparities in pediatric patients, and fewer still have looked for racial/ethnic differences in treatment outcomes in pediatric brain cancer patients.

A study by University of Colorado Cancer Center investigators working at Children's Hospital Colorado not only confirms worse outcomes for Black and Hispanic pediatric brain cancer patients (compared with non-Hispanic whites), but hints at where in the process of diagnosis and treatment these disparities arise.

Patients whose cancer has already spread by the time they are diagnosed have a poorer prognosis. But the current study finds that at the time of diagnosis, pediatric brain tumor patients of all races/ethnicities presented with cancers of similar stage and aggressiveness - in other words, at the point of diagnosis, there were no disparities. However, Black and Hispanic patients then went on to fare worse than non-Hispanic White patients. Together, these findings suggest that it's not the process of diagnosis, but during the process of treatment and follow-up that the paths of minority and White pediatric brain cancer patients diverge.

"We were surprised," says the study's senior author, Adam Green, MD, CU Cancer Center investigator and pediatric brain cancer specialist at Children's Hospital Colorado. "In general, we expect these disparities to be multi-factorial and have pre- and post-diagnosis components, but these findings suggest these patients are able to get diagnosed appropriately, but after that, treatment and follow up may be where the disparities lie."

Overall, of 1,881 patients under age 19 diagnosed with cancers of the brain and central nervous system between 2000 and 2015, 52 percent of White patients lived five years from diagnosis, whereas only 44 percent of African American patients and 45 percent of Hispanic patients reached a similar milestone.

"If we look overall in pediatric brain and central nervous system cancers, Black and Hispanic patients have a higher risk of dying from these tumors compared with non-Hispanic White patients," Green says. "Even when they presented with similar stage disease as their White counterparts, they still did worse."

Future studies are planned to look deeper into the source of these disparities, but Green suggests there are some obvious factors that health care systems can work on now to ensure equal care and, hopefully, more equal outcomes.

"One thing we don't talk about enough in cancer is how much of a burden going through treatment is on families - financial resources, transportation resources, time resources, shelter and lodging resources, etc.," Green says. "We can plan an effective treatment, but if there are life factors that make it more challenging for some families to get that entire course of treatment successfully, then all the planning we do isn't going to make the treatment as effective as we would like it to be."

Green also suggests that due to the complexity of many of these cases, young brain cancer patients should be seen at centers with experience treating these cancers and that offer multi-disciplinary care, allowing patients to access experts in many different fields including medical oncology, surgery, radiation, pathology, and supportive care such as palliative medicine and even nutrition.

"It's incumbent on us to make sure these families have access to the resources they need to ensure that their children are able to get the highest quality care," Green says.

University of Colorado Anschutz Medical Campus

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to